• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    贝

    贝勒斯科特和怀特健康中心

    Baylor Scott & White Health
    EST. 1897
    1,410论文总数
    2.8万引用总数

    Baylor Scott & White Health is a healthcare system based in Dallas, Texas, United States. Formed in 2013 from the merger of Scott & White Health with Baylor Healthcare System, it became the largest non-profit healthcare system in Texas, and one of the largest in the country. Its network contains over 50 hospitals and more than 800 patient care sites.

    论文量&引用量时间轴

    机构学者

    论文(1410)

    年份
    起
    –
    止
    排序
    1Gut Microbial Histamine and Serotonin Promote Cerebrovascular Angiogenesis: Evidence from Moyamoya Disease
    Haiyan Tian, Lilan Zhu, Yuheng Zhang, Mengwei Chen, Xueying Zuo, Yi Wu, Hanzhen Wang, Zheng Lv,Qing Huang,Min Wu,Erxi Wu, Jinsheng Zeng,

    Moyamoya disease (MMD) is a progressive cerebrovascular disorder characterized by arterial stenosis and compensatory neovascularization, but its upstream drivers remain poorly defined. Here, we identify Bifidobacterium pseudocatenulatum (B. pseudocatenulatum), a traditionally probiotic species, as a context-dependent pathobiont. Integrated metagenomic and metabolomic analyses revealed enrichment of B. pseudocatenulatum in MMD, closely associated with elevated microbial-derived histamine and serotonin. In mice, chronic oral administration of B. pseudocatenulatum disrupted intestinal barrier integrity and increased gut microbial production and systemic levels of histamine and serotonin. These changes were accompanied by systemic inflammation and activation of angiogenic pathways, which together promoted MMD-relevant cerebrovascular remodeling in experimental models. Notably, direct administration of histamine or serotonin to mice reproduced key MMD-like vascular phenotypes, supporting the conclusion that these microbial metabolites are sufficient to induce selected MMD-relevant vascular changes in experimental models. Our findings propose a microbial–metabolite–vascular axis and suggest that the role of specific Bifidobacterium strains may be more nuanced than previously recognized. These results provide a mechanistic framework for understanding the gut–brain axis in neurovascular pathology and nominate the microbiome and its metabolic products as potential targets for non-invasive diagnostics and precision therapeutic interventions in MMD.

    2027Genes & Diseases(2027)
    引用
    AI阅读
    加入学术空间
    2The Society of Thoracic Surgeons Expert Consensus Pathway for Robotic Cardiac Surgical Training
    Vinay Badhwar,Arman Arghami,Štěpán Černý,Daniel Pereda, Danny Ramzy, Nirav Patel,Joanna Chikwe,Jessica Rove, J Michael Smith,Wouter Oosterlinck,Joerg Kempfert,Gregory Pattakos,

    The Society of Thoracic Surgeons (STS) 2026 Expert Consensus Pathway on Robotic Cardiac Training outlines principles for the safe initial introduction and subsequent expansion of robotic cardiac programs. The 25-year history of robotic cardiac surgery has established safety and efficacy while providing multiple innovations. There is currently a unique opportunity to coalesce best practices and evidence to inform a recent global surge in interest in incorporating robotic techniques into standard cardiac surgical practice. This consensus is a collaborative effort between the STS Workforce on Evidence Based Surgery, the STS Robotic Cardiac Surgery Taskforce, and multinational leaders in robotic cardiac surgery that aims to standardize initial core principles of preparatory elements, followed by 4 phases of robotic cardiac training to proceed from program commencement to mastery.

    2026The Annals of thoracic surgery(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Gut Microbiota Modulation Via Repeated Donor Fecal Transplantation Improves Motor and Gastrointestinal Symptoms in Drug-Naïve Parkinson's Disease: a Randomized Phase 2 Trial.
    Rui Zhang, Renyi Feng, Jiuqi Wang,Yongkang Chen,Han Liu, Qingyong Zhu, Haiyan Tian,Chi Qin,Junfang Teng,Beisha Tang, Min Wu,Jinsheng Zeng,

    The gut-brain axis is increasingly recognized as a critical contributor to Parkinson's disease (PD) pathogenesis, yet the therapeutic impact of microbiota modulation remains unclear due to lack of clinical trials in drug-naïve patients. We conducted a randomized, double-blind, placebo-controlled phase 2 trial to evaluate the safety, tolerability, and efficacy of repeated donor fecal microbiota transplantation (dFMT) in de novo PD. FMT was administered for seven days (200 mL on days 1-3; 50 mL on days 4-7) per 4-week cycle. Seventy-two patients were randomized 1:1 to receive dFMT or autologous FMT (aFMT), and 66 completed the trial. At 35 weeks, the dFMT group showed significant improvement in motor symptoms (mean change in Unified Parkinson's Disease Rating Scale [UPDRS] III: -3.8 vs. +0.1; p = 0.0001) and a substantially greater reduction in constipation severity (dFMT vs. aFMT: -6.5 vs. -0.7; p < 0.0001), accompanied by improved quality-of-life scores. Microbiome profiling revealed greater similarity to donor composition and a marked reduction in Escherichia-Shigella, correlating with decreased colonic α-synuclein aggregation (r = 0.3775, p = 0.0277), supporting a gut-brain mechanistic link. Biochemical analyses showed elevated fecal dopamine and 3,4-dihydroxyphenylacetic acid levels, while histological assessments demonstrated strengthened epithelial barrier integrity with increased E-cadherin expression. All adverse events were mild and self-limited; no serious treatment-related events were observed. These findings demonstrate that repeated dFMT is safe, well tolerated, and yields clinically meaningful motor and gastrointestinal improvements in drug-naïve PD, providing integrated mechanistic and clinical evidence that microbiota-targeted modulation represents a promising nonpharmacologic therapeutic strategy for neurodegenerative disease. Trial registration: Chinese Clinical Trial Registry, ChiCTR2200064151.

    2026Signal transduction and targeted therapy(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Tailoring Heart Failure Management in Cardiac Amyloidosis.
    Ernesto Ruiz Duque, Nikolaos-lason Tepetes, Chris Kourek, Ibrahim Mortada, Adamantia Papamichail,Efstathios Kastritis,Kimon Stamatelopoulos,Alexandros Briasoulis,Rabea Asleh

    Cardiac amyloidosis is an infiltrative cardiomyopathy caused by extracellular deposition of amyloid fibrils, most commonly from immunoglobulin light chain (AL) or transthyretin (ATTR) proteins. Cardiac involvement dictates prognosis, with restrictive physiology, diastolic dysfunction, and conduction disease leading to progressive heart failure. Management of heart failure in cardiac amyloidosis differs fundamentally from conventional heart failure strategies. Due to preload dependence, autonomic dysfunction, and poor tolerance of standard therapies, treatment focuses on cautious volume control using low-dose diuretics, while β-blockers and ACE inhibitors, are used sparingly. Mineralocorticoid receptor antagonists are generally well tolerated and commonly used, with monitoring for hyperkalemia and renal dysfunction. Disease-specific therapy has revolutionized outcomes: daratumumab-based chemotherapy in AL amyloidosis achieves rapid and deep hematologic responses, improving cardiac biomarkers, imaging parameters, and survival. In the ATTR-subtype, transthyretin stabilizers and silencers significantly reduce mortality, cardiovascular hospitalizations, and functional decline, especially when initiated early. Atrial fibrillation and conduction disease are common; anticoagulation is indicated irrespective of CHA₂DS₂-VASc score. Ιmplantable cardioverter-defibrillator and cardiac resynchronization therapy are reserved for standard indications, with limited survival benefit. Inotropes serve as palliative or bridge therapy in end-stage disease, while transplantation remains viable in selected patients with controlled systemic disease. Emerging TTR stabilizers, gene silencers, and fibril-clearing antibodies may further transform prognosis. Advances in imaging, digital monitoring, and multidisciplinary care aim to enhance early detection and individualized management. Timely diagnosis, evidence-based therapy, and coordinated multidisciplinary care are essential to optimize survival and quality of life in cardiac amyloidosis.

    2026Heart Failure Reviews(2026)
    引用
    AI阅读
    加入学术空间
    5Reconstruction of a Large Multisubunit Defect of the Medial Canthus, Nasal Sidewall, and Eyelid.
    Oliver Ha, Marcus Zaayman, Chad Housewright
    2026Dermatologic surgery official publication for American Society for Dermatologic Surgery et al(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1410 篇论文

    合作机构(100)

    贝勒大学合作论文 51
    密歇根大学合作论文 49
    德州农工大学系统合作论文 44
    哥伦比亚大学合作论文 44
    华盛顿大学合作论文 43
    德克萨斯 A&M 大学合作论文 38
    Texas A&M University–Kingsville合作论文 38
    匹兹堡大学合作论文 36
    斯坦福大学合作论文 35
    科罗拉多州立大学合作论文 34

    机构统计